Products Description
Oxygen-Scavenging PVC/PVDC Film for Long-Term Protection of Oxidation-Sensitive Drugs
A multi-layer PVC/PVDC film with a permanently integrated, pharmaceutical-grade oxygen scavenging system within its inner sealant layer. It actively and irreversibly removes residual and permeating oxygen from the blister cavity, transitioning primary packaging from a passive barrier to an active stability-enhancing component.
1. Pharmaceutical Challenge: Overcoming the Limits of Passive Barrier Technology
For oxidation-sensitive Active Pharmaceutical Ingredients (APIs)-including many cardiovascular agents, specific peptides, unsaturated biologics, and essential vitamins-molecular degradation begins with the oxygen present at the moment of sealing. Traditional high-barrier films only slow the rate of new ingress. This passive approach leaves the drug's stability at the mercy of initial package headspace and the inevitable, cumulative permeation over time, often forcing formulators to use excessive and costly antioxidant overages that may affect bioavailability.
OxiGuard™ APS addresses this fundamental limitation. By deploying controlled active chemistry within the packaging itself, it directly tackles the root cause of oxidative degradation, providing a level of protection that passive materials cannot achieve.
2. Mechanism of Action: Precision Chemistry for Drug Stability
The efficacy of OxiGuard™ APS stems from its engineered, non-migrating scavenging agents dispersed in the film layer facing the drug product.
Moisture-Activated, Reaction-Limited System: The scavenging compounds are chemically inert during film manufacturing and storage. They activate only upon exposure to the specific moisture level inside a sealed pharmaceutical blister (typically provided by the dosage form itself). This targeted activation ensures full scavenging capacity is reserved for the product's service life.
Two-Stage Protective Action:
Primary Scavenging Phase (Weeks 1-8): Rapidly consumes >95% of the trapped headspace oxygen, reducing internal O₂ concentration to <100 ppm within 60 days under ambient conditions.
Long-Term Stabilization Phase: Continues to react with oxygen molecules that diffuse through the film barrier over years, maintaining an ultra-low oxygen environment. This system effectively extends the "induction period" of API oxidation indefinitely for standard shelf-life durations.
Safety by Design: All scavenging components are selected from GRAS (Generally Recognized as Safe) listings and are immobilized within a polymer matrix, preventing any migration into the drug product. Full extractables & leachables profiles are available.
3. Quantifiable Performance & Stability Advantages
The film's value is demonstrated through direct comparative stability data, offering clear ROI through enhanced drug product performance.
| Performance Parameter | Test Method / Condition | OxiGuard™ APS Result | Implication for Drug Product |
|---|---|---|---|
| Headspace Oxygen Reduction | Dynamic via fiber-optic sensor (23°C, sealed with dry N₂ placebo) | Reduction to <0.1% v/v within 28 days. | Near-elimination of the primary oxidative driver immediately post-packaging. |
| Shelf-Life Projection | Accelerated stability at 40°C/75% RH measuring primary oxidation impurity. | Time to reach specification limit extended by 2.3x vs. identical passive high-barrier film. | Enables longer market shelf-life claims (e.g., 36 months instead of 24). |
| Protection Against Variable Fill Gases | Sealed with ambient air (21% O₂) to simulate line fault. | Internal O₂ reduced to <0.5% within 14 days. | Adds robust process forgiveness, mitigating risks from packaging line inconsistencies. |
| Compatibility with Common APIs | 6-month real-time study with sensitive Vitamin E formulation. | >95% potency retention vs. 82% with control film. | Directly preserves API potency, reducing required overage and impro |
4. Target Pharmaceutical Applications
This film is a critical tool for specific drug development and lifecycle management challenges:
New Molecular Entities (NMEs) with oxidative degradation pathways identified in pre-formulation.
Biosimilars where matching or exceeding the originator's stability profile is crucial for approval and market penetration.
Reformulation Projects aimed at reducing antioxidant excipients to create cleaner labels or improve tolerability.
High-Potency & Low-Dose Drugs where even minor degradation can significantly impact therapeutic dose accuracy.
Global Supply Chain Products requiring extra stability margin for hot/humid climate zones.
5. Technical Specifications & Integration
| Category | Specification | Details |
|---|---|---|
| Base Film Structure | Multi-layer co-extrusion | PVC structural layer / PVDC passive barrier / Functional O₂-scavenging sealant layer. |
| Passive Barrier (WVTR/OTR) | ASTM F1249 / D3985 | Maintains high-barrier performance: WVTR < 0.8 g/m²/day, OTR < 18 cm³/m²/day. |
| Scavenging Capacity | In-house volumetric method | Standard grade: ≥ 25 cc O₂ per m² of film. High-capacity grade available. |
| Activation Requirement | -- | Requires typical product moisture (>1% RH in headspace). Not for use with absolutely anhydrous products. |
| Processing Parameters | Thermoforming & Sealing | Identical to standard PVC/PVDC films. Sealing jaw temperature may be optimized ±5°C. |
| Regulatory Status | Compliance | Components comply with FDA 21 CFR, EU 10/2011, and other major pharmacopoeia for food/pharma contact. |
6. Partnership & Implementation Support
Adopting active packaging is a strategic decision. We support it with a risk-mitigated pathway:
Feasibility Testing Kit: We provide a kit with film samples and vials containing a sensitive oxidative indicator for a simple, conclusive 14-day performance test in your lab.
Stability Study Bridging Support: We supply matched samples of OxiGuard™ APS and a conventional control film for your side-by-side accelerated stability studies, generating the critical comparative data for regulatory assessment.
Technical Dossier: A comprehensive package including a Drug Master File (DMF) reference, toxicological risk assessment, and recommended quality control checks for incoming film.
Hot Tags: oxygen-scavenging pvc/pvdc film for long-term protection of oxidation-sensitive drugs, China, manufacturers, suppliers, factory, customized, custom, wholesale, low price, free sample
